United States
Premiumsupplier
PIM447 CAS NO.1210608-43-7
- Min.Order: 1 Gram
- Payment Terms: L/C
- Product Details
Keywords
- N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
- PIM447
- CHEMBL3651966
Quick Details
- ProName: PIM447
- CasNo: 1210608-43-7
- Molecular Formula: C24H23F3N4O
- Appearance: Powder
- Application: This active molecular is a potent PIM ...
- DeliveryTime: 7 days
- PackAge: inquiry
- Port: inquiry
- ProductionCapacity: 10 Kilogram/Month
- Purity: 98%
- Transportation: inquiry
- LimitNum: 1 Gram
Superiority
This active molecular is a potent PIM 1, 2, and 3 kinase inhibitor under the development of Novartis. In vivo, PIM447 reduces the tumor burden and also preventes tumor-associated bone loss in a disseminated murine model of human myeloma. In vitro, it inhibits osteoclast formation and resorption. Moreover, it increases osteoblast activity and mineralization. In May 2016, Novartis completed a phase I trial for Multiple myeloma (Second-line treatment or greater) in Japan. #
Details
This active molecular is a potent PIM 1, 2, and 3 kinase inhibitor under the development of Novartis. In vivo, PIM447 reduces the tumor burden and also preventes tumor-associated bone loss in a disseminated murine model of human myeloma. In vitro, it inhibits osteoclast formation and resorption. Moreover, it increases osteoblast activity and mineralization. In May 2016, Novartis completed a phase I trial for Multiple myeloma (Second-line treatment or greater) in Japan. #